Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Microbix Biosystms J (TSE:MBX)
TSX:MBX
RESEARCH TOOLSreports
Microbix Biosystms (MBX) Stock Price & Analysis
22 Followers
MBX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.23 - C$0.47
Previous CloseC$0.36
Volume5.50K
Average Volume (3M)71.56K
Market Cap
C$48.48M
Enterprise ValueC$42.37M
Total Cash (Recent Filing)C$12.78M
Total Debt (Recent Filing)C$6.68M
Price to Earnings (P/E)13.1
Beta0.23
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding136,853,373
10 Day Avg. Volume38,829
30 Day Avg. Volume71,556
Standard Deviation0.13
R-Squared0.00748
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.09
Price to Sales (P/S)2.91
Price to Cash Flow (P/CF)8.90
P/FCF Ratio7.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.10Price Target Upside209.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Microbix Biosystms News
PremiumCompany Announcements
Microbix Biosystems Announces Q2 Results Webinar
PremiumCompany Announcements
Microbix Boosts STI Testing with New Lab ProgramPremiumCompany Announcements
Microbix Biosystems to Present at Healthcare Conference
PremiumPress Releases
Microbix’s Clot-Buster Drug Project Advances
PremiumCompany Announcements
Microbix Launches Oncology Test Controls
Bulls Say, Bears Say
Bulls Say
Product ApprovalThe HSV 1+2/VZV panel was approved, potentially leading to significant revenue growth with the anticipation of more tests being approved.
Sales GrowthAntigen sales are on an upward trend, recovering to levels that could soon match the pre-pandemic demand.
Strategic PartnershipsThe recent FDA clearance for QuidelOrtho's Savanna PCR platform may boost future sales of QAPs, highlighting Microbix's strategic partnerships.
Bears Say
Financial PerformanceEBITDA came in lower than expected as operating costs rose due to higher G&A costs and one-time expenses.
Profitability4Q gross margin was 33%, down from 47% during the same period last year due to large orders of low margin antigens and increased antigen batch failures.
Sales PerformanceRevenues decreased 1% Y/Y with no DxTM sales, post-COVID.
---
Options Prices
Currently, No data available
---
Ownership Overview
20.55% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
79.45% Public Companies and
Individual Investors
MBX FAQ
What was Microbix Biosystms J’s price range in the past 12 months?
Microbix Biosystms J lowest stock price was C$0.23 and its highest was C$0.47 in the past 12 months.
What is Microbix Biosystms J’s market cap?
Currently, no data Available
When is Microbix Biosystms J’s upcoming earnings report date?
Microbix Biosystms J’s upcoming earnings report date is May 09, 2024 which is yesterday.
How were Microbix Biosystms J’s earnings last quarter?
Microbix Biosystms J released its earnings results on Feb 14, 2024. The company reported C$0.018 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.018.
Is Microbix Biosystms J overvalued?
According to Wall Street analysts Microbix Biosystms J’s price is currently Undervalued.
Does Microbix Biosystms J pay dividends?
Microbix Biosystms J does not currently pay dividends.
What is Microbix Biosystms J’s EPS estimate?
Microbix Biosystms J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microbix Biosystms J have?
Microbix Biosystms J has 136,550,370 shares outstanding.
What happened to Microbix Biosystms J’s price movement after its last earnings report?
Microbix Biosystms J reported an EPS of C$0.018 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Microbix Biosystms J?
Currently, no hedge funds are holding shares in TSE:MBX
---
Microbix Biosystms Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$1.10 (209.86% Upside)
C$1.10 (209.86% Upside)
Insider Transactions
Sold Shares
Worth C$108.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.50%
12-Months-Change
Fundamentals
Return on Equity
14.66%
Trailing 12-Months
Asset Growth
12.27%
Trailing 12-Months
Company Description
Microbix Biosystms J
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company operates in two industries: the development, manufacturing, and distribution of cell-based products and technology and, the provision of the facility, technical and production personnel for contract research and development. Microbix operates in three principal geographical areas: North America, Europe and in other foreign countries. It derives most of its revenue from Europe.
---
MBX Stock 12 Month Forecast
Average Price Target
C$1.10
▲(209.86% Upside)
Technical Analysis
Helix BioPharma
―
Tetra Bio-Pharma
―
Eupraxia Pharmaceuticals
―
ProMIS Neurosciences
―
Best Analysts Covering MBX
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-12.50%
reiterated a buy rating 3 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -12.50% per trade.
---